BiotechTube

ABP-450

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cervical Dystonia

Conditions

Cervical Dystonia

Trial Timeline

Jul 27, 2021 → Jul 24, 2023

NCT ID
NCT04871451

About ABP-450

ABP-450 is a phase 2 stage product being developed by AEON Biopharma for Cervical Dystonia. The current trial status is completed. This product is registered under clinical trial identifier NCT04871451. Target conditions include Cervical Dystonia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT05016661Phase 2Terminated
NCT04871451Phase 2Completed

Competing Products

20 competing products in Cervical Dystonia

See all competitors
ProductCompanyStageHype Score
PRGN-2009 plus Pembrolizumab + Pembrolizumab alonePrecigenPhase 2
47
ABP-450 + PlaceboAEON BiopharmaPhase 2
44
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Sacituzumab tirumotecan plus IparomlimabSun PharmaceuticalPhase 2
52
Amolimogene + AmolimogeneEisaiPhase 2/3
65
BOTULINUM TOXIN TYPE BEisaiPhase 2
52
Gemzar (gemcitabine)Eli LillyPhase 3
77
PemetrexedEli LillyPhase 2
52
SHR-A1811 InjectionJiangsu Hengrui MedicinePhase 2
52
camrelizumab； famitinib malate + platinum-based chemotherapyJiangsu Hengrui MedicinePhase 3
77
SHR-1210 + SHR-1020 + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + Cisplatin or CarboplatinJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + Cisplatin or CarboplatinJiangsu Hengrui MedicinePhase 2
52
Volrustomig + Cisplatin + Carboplatin + PaclitaxelAstraZenecaPhase 2
52
VolrustomigAstraZenecaPhase 3
77
Durvalumab + Cisplatin + CarboplatinAstraZenecaPhase 3
77
VolrustomigAstraZenecaPhase 2
52
PembrolizumabMerckPhase 2
52

Other Products from AEON Biopharma

ABP-450 + PlaceboPhase 2
44
ABP-450Phase 2
44
ABP-450 + PlaceboPhase 2
44